Compare IND. SWIFT with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IND. SWIFT vs ORTIN LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IND. SWIFT ORTIN LABS IND. SWIFT/
ORTIN LABS
 
P/E (TTM) x -3.2 17.6 - View Chart
P/BV x - 2.4 - View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 IND. SWIFT   ORTIN LABS
EQUITY SHARE DATA
    IND. SWIFT
Mar-21
ORTIN LABS
Mar-21
IND. SWIFT/
ORTIN LABS
5-Yr Chart
Click to enlarge
High Rs535 14.2%   
Low Rs27 27.3%   
Sales per share (Unadj.) Rs65.710.0 654.4%  
Earnings per share (Unadj.) Rs-5.51.2 -473.6%  
Cash flow per share (Unadj.) Rs0.51.5 35.2%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs-128.414.0 -918.9%  
Shares outstanding (eoy) m54.168.13 666.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.12.1 2.5%   
Avg P/E ratio x-0.618.0 -3.4%  
P/CF ratio (eoy) x6.413.8 46.3%  
Price / Book Value ratio x01.5 -1.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m184170 108.6%   
No. of employees `000NANA-   
Total wages/salary Rs m5129 5,999.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,56182 4,359.7%  
Other income Rs m1521 30,442.0%   
Total revenues Rs m3,71382 4,517.9%   
Gross profit Rs m40212 3,226.3%  
Depreciation Rs m3273 11,474.7%   
Interest Rs m5229 5,976.9%   
Profit before tax Rs m-2951 -21,686.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3-8 -39.9%   
Profit after tax Rs m-2989 -3,155.1%  
Gross profit margin %11.315.2 74.0%  
Effective tax rate %-1.1-594.9 0.2%   
Net profit margin %-8.411.6 -72.3%  
BALANCE SHEET DATA
Current assets Rs m2,65261 4,329.4%   
Current liabilities Rs m7,06279 8,954.6%   
Net working cap to sales %-123.9-21.6 574.5%  
Current ratio x0.40.8 48.3%  
Inventory Days Days15315 1,024.3%  
Debtors Days Days1,107174,959,293 0.0%  
Net fixed assets Rs m4,064151 2,684.1%   
Share capital Rs m10881 133.2%   
"Free" reserves Rs m-7,06032 -21,898.2%   
Net worth Rs m-6,952114 -6,121.6%   
Long term debt Rs m6,44214 44,671.8%   
Total assets Rs m6,716213 3,158.0%  
Interest coverage x0.41.2 37.6%   
Debt to equity ratio x-0.90.1 -729.7%  
Sales to assets ratio x0.50.4 138.1%   
Return on assets %3.38.6 38.9%  
Return on equity %4.38.3 51.5%  
Return on capital %-44.57.9 -563.7%  
Exports to sales %74.20-   
Imports to sales %5.00-   
Exports (fob) Rs m2,643NA-   
Imports (cif) Rs m176NA-   
Fx inflow Rs m2,6820-   
Fx outflow Rs m2600-   
Net fx Rs m2,4220-   
CASH FLOW
From Operations Rs m772180 428.3%  
From Investments Rs m-1671 -23,875.7%  
From Financial Activity Rs m-483-99 489.9%  
Net Cashflow Rs m12282 148.4%  

Share Holding

Indian Promoters % 55.6 15.7 354.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 44.5 84.3 52.7%  
Shareholders   13,596 12,819 106.1%  
Pledged promoter(s) holding % 73.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IND. SWIFT With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IND. SWIFT SHARE PRICE


Jan 21, 2022 (Close)

TRACK IND. SWIFT

  • Track your investment in IND. SWIFT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IND. SWIFT 8-QTR ANALYSIS

COMPARE IND. SWIFT WITH

MARKET STATS